Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Vaccine for Pancreatic Tumor
NCT03558945Phase 1Unknown
- Sponsor
- Anda Biopharmaceutical Development
- Start
- Jul 2018
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of personalized neoantigen vaccine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Anda Biopharmaceutical Development. Primary endpoint: Incidence and grades of adverse events at 2 years. Status: unknown.
02
Drugs
personalized neoantigen vaccine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03558945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558945.